$2 Trillion Disappears Because of Fed's Secretive New Move

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Michelle Robertson net worth and biography

Michelle Robertson Biography and Net Worth

CFO of Editas Medicine

Michelle Robertson serves as Chief Financial Officer of the Company. Ms. Robertson previously served as the Chief Financial Officer of Momenta Pharmaceuticals, Inc. ("Momenta"), a publicly traded biotechnology company, from October 2018 until January 2020, and as Vice President, Financial Planning and Analysis of Momenta from May 2017 to October 2018. Prior to joining Momenta, Ms. Robertson was Vice President, Oncology Finance for Baxalta, Inc., a biopharmaceutical company, following its spin-off from Baxter International, from 2015 to 2016. From 2012 to 2015, Ms. Robertson served as Head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, Inc., and prior to that, held various leadership positions in the Oncology and Biosurgery divisions of Finance and Commercial Operations at Genzyme Corporation (now Sanofi Genzyme), a biotechnology company. Ms. Robertson received her B.S. in Finance and A.S. in Accounting and Management from Bentley University.

What is Michelle Robertson's net worth?: The estimated net worth of Michelle Robertson is at least $139,659.10 as of May 11th, 2023. Ms. Robertson owns 106,610 shares of Editas Medicine stock worth more than $139,659 as of December 22nd. This net worth estimate does not reflect any other assets that Ms. Robertson may own. Learn More about Michelle Robertson's net worth.
How do I contact Michelle Robertson?: The corporate mailing address for Ms. Robertson and other Editas Medicine executives is 11 Hurley Street, Cambridge MA, 02141. Editas Medicine can also be reached via phone at (617) 401-9000 and via email at [email protected]. Learn More on Michelle Robertson's contact information.
Has Michelle Robertson been buying or selling shares of Editas Medicine?: Michelle Robertson has not been actively trading shares of Editas Medicine over the course of the past ninety days. Most recently, Michelle Robertson sold 949 shares of the business's stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $9.87, for a transaction totalling $9,366.63. Following the completion of the sale, the chief financial officer now directly owns 106,610 shares of the company's stock, valued at $1,052,240.70. Learn More on Michelle Robertson's trading history.
Who are Editas Medicine's active insiders?: Editas Medicine's insider roster includes Katrine Bosley (CEO), Bruce Eaton (EVP), Lisa Michaels (EVP), James Mullen (CEO), and Michelle Robertson (CFO). Learn More on Editas Medicine's active insiders.
Are insiders buying or selling shares of Editas Medicine?: During the last year, Editas Medicine insiders bought shares 1 times. They purchased a total of 45,000 shares worth more than $253,800.00. During the last year, insiders at the sold shares 10 times. They sold a total of 133,590 shares worth more than $1,104,930.91. The most recent insider tranaction occured on December, 3rd when CEO Gilmore Neil O'neill sold 1,618 shares worth more than $3,365.44. Insiders at Editas Medicine own 1.9% of the company. Learn More about insider trades at Editas Medicine.
Information on this page was last updated on 12/3/2024.

Michelle Robertson Insider Trading History at Editas Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/11/2023	Sell	949	$9.87	$9,366.63	106,610
3/3/2023	Sell	184	$8.89	$1,635.76	107,559
2/13/2023	Sell	4,287	$9.67	$41,455.29	76,243
1/10/2023	Sell	1,752	$8.16	$14,296.32	80,530
6/3/2022	Sell	1,527	$11.54	$17,621.58	82,667
3/3/2022	Sell	767	$17.33	$13,292.11
1/11/2022	Sell	1,744	$25.70	$44,820.80
6/28/2021	Sell	2,500	$50.00	$125,000.00
1/12/2021	Sell	1,568	$78.27	$122,727.36	18,432

Michelle Robertson Buying and Selling Activity at Editas Medicine

Editas Medicine Company Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Today's Range

Now: $1.31

$1.28

$1.38

50 Day Range

MA: $2.58

$1.31

$3.76

2 Week Range

Now: $1.31

$1.28

$11.58

Volume

4,216,381 shs

Average Volume

2,049,668 shs

Market Capitalization

$108.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

$2 Trillion Disappears Because of Fed's Secretive New Move

From Stansberry Research | Ad

Click here to see his new research now.